阿替利珠单抗联合白蛋白紫杉醇治疗转移性三阴性乳腺癌:1b期试验2年生存随访
该1b期多队列研究纳入33例转移性三阴性乳腺癌女性,接受阿替利珠单抗联合白蛋白紫杉醇治疗,中位随访24.4个月。主要终点安全耐受,3/4级不良事件发生率73%,客观缓解率39.4%,中位无进展生存5.5个月,中位总生存14.7个月,联合治疗未显著改变肿瘤免疫微环境标志物。
要点
- 联合方案安全可控,无治疗相关死亡
- 客观缓解率39.4%,中位缓解持续时间9.1个月
- 中位无进展生存5.5个月,中位总生存14.7个月
核心结论
- 阿替利珠单抗联合白蛋白紫杉醇在转移性三阴性乳腺癌中安全性可控,并观察到抗肿瘤应答。
研究设计与样本
- 中位随访24.4个月(95%CI 22.1-28.8个月)。
主要发现
- 所有患者(100%)发生至少1例治疗相关不良事件,24例(73%)发生3/4级不良事件,7例(21%)发生特别关注的3/4级不良事件,无治疗相关死亡。
- 客观缓解率39.4%(95%CI 22.9%-57.9%),中位缓解持续时间9.1个月(95%CI 2.0-20.9个月),疾病控制率51.5%(95%CI 33.5%-69.2%)。
- 中位无进展生存5.5个月(95%CI 5.1-7.7个月),中位总生存14.7个月(95%CI 10.1-不可估计)。
- 同步白蛋白紫杉醇未显著改变肿瘤免疫微环境标志物(PD-L1、肿瘤浸润淋巴细胞、CD8),也未损害阿替利珠单抗的系统免疫激活(增殖性CD8+ T细胞扩增、CXCL10趋化因子增加)。
临床怎么用
- 对于转移性三阴性乳腺癌,阿替利珠单抗联合白蛋白紫杉醇可作为兼顾疗效与安全性的治疗选择之一。
- 治疗期间需密切监测3/4级不良事件,尤其是特别关注的不良事件。
局限性
- 本研究为1b期单臂试验,样本量33例,无对照组,结论需更大规模随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The humanized monoclonal antibody atezolizumab targets programmed death-ligand 1 and has demonstrated durable single-agent activity in a subset of metastatic triple-negative breast cancers. To extend the observed activity, combinatorial approaches are being tested with standard cytotoxic chemotherapies known to induce immunogenic tumor cell death. OBJECTIVE: To examine the safety, tolerability, and preliminary clinical activity of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancers. DESIGN, SETTING, AND PARTICIPANTS: This phase 1b multicohort study enrolled 33 women with stage IV or locally recurrent triple-negative breast cancers and 0 to 2 lines of prior chemotherapy in the metastatic setting from December 8, 2014, to April 30, 2017, at 11 sites in the United States. The median follow-up was 24.4 months (95% CI, 22.1-28.8 months). INTERVENTIONS: Patients received concurrent intravenous atezolizumab and intravenous nab-paclitaxel (minimum 4 cycles). MAIN OUTCOMES AND MEASURES: The primary end point was safety and tolerability. Secondary end points included best overall response rate by Response Evaluation Criteria in Solid Tumors, version 1.1; objective response rate; duration of response; disease control rate; progression-free survival; overall survival; and biomarker analyses. RESULTS: The 33 women had a median age of 55 years (range, 32-84 years) and received 1 or more doses of atezolizumab. All patients (100%) experienced at least 1 treatment-related adverse event, 24 patients (73%) experienced grade 3/4 adverse events, and 7 patients (21%) had grade 3/4 adverse events of special interest. No deaths were related to study treatment. The objective response rate was 39.4% (95% CI, 22.9%-57.9%), and the median duration of response was 9.1 months (95% CI, 2.0-20.9 months). The disease control rate was 51.5% (95% CI, 33.5%-69.2%). Median progression-free survival and overall survival were 5.5 months (95% CI, 5.1-7.7 months) and 14.7 months (95% CI, 10.1-not estimable), respectively. Concurrent nab-paclitaxel neither significantly changed biomarkers of the tumor immune microenvironment (programmed death-ligand 1, tumor-infiltrating lymphocytes, CD8) nor impaired atezolizumab systemic immune activation (expansion of proliferating CD8+ T cells, increase of CXCL10 chemokine). CONCLUSIONS AND RELEVANCE: In this phase 1b trial for metastatic triple-negative breast cancers, the combination of atezolizumab plus nab-paclitaxel had a manageable safety profile. Antitumor responses were observed, including in patients previously treated with a taxane. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01633970.
引用
- Adams S, Diamond JR, Hamilton E, et al. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA Oncol. 2019. PMID: 30347025. doi:10.1001/jamaoncol.2018.5152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。